Skip to main content

Advertisement

SpringerLink
Log in

Decreased Expression of RASSF6 Is a Novel Independent Prognostic Marker of a Worse Outcome in Gastric Cancer Patients after Curative Surgery

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Our previous study observed that the expression of RASSF6, a member of the Ras-association domain family, was down-regulated in gastric cancer cells. The present study further investigated the clinical significance of RASSF6 in gastric cancer.

Methods

Using real-time PCR, Western blot analysis, tissue microarray (TMA), and immunohistochemical staining, we evaluated RASSF6 mRNA and protein levels in tumor tissues and in the paired adjacent normal mucosa from patients with gastric cancers at different stages.

Results

RASSF6 mRNA and protein levels were decreased in gastric cancer tissues compared with the adjacent normal mucosa. Immunohistochemical detection of RASSF6 in a TMA that contained 264 paired specimens showed that a decreased cytoplasmic RASSF6 expression was significantly associated with the extent of cancer invasion, lymph node metastasis, distant metastasis, tumor histological grade, advanced clinical stage, and Ki-67 proliferative index. Moreover, RASSF6 expression in metastatic lymph nodes was lower than in the paired primary tumors. Patients with RASSF6-negative tumors had extremely higher disease recurrence rates and poorer survival than patients with RASSF6-positive tumors even after radical surgery. Stratification analysis revealed RASSF6 as an independent predictor for tumor recurrence in patients with gastric cancers irrespective of tumor stage.

Conclusions

RASSF6 might contribute to the progression of gastric carcinogenesis and may function as a novel independent prognostic marker for the prediction of the recurrence of cancer in patients after curative operations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9:279–87.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  3. Cunningham D, Oliveira J. Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:ii23–4.

    Article  PubMed  Google Scholar 

  4. de Maat MF, van de Velde CJ, Umetani N, et al. Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. J Clin Oncol. 2007;25(31):4887–94.

    Article  PubMed  Google Scholar 

  5. MacDonald JS. Gastric cancer: new therapeutic options. N Engl J Med. 2006;355:76–7.

    Article  PubMed  CAS  Google Scholar 

  6. Hundahl SA, Wanebo HJ. Changing gastric cancer treatment in the United States and the pursuit of quality. Eur J Surg Oncol. 2005;31:605–15.

    Article  PubMed  CAS  Google Scholar 

  7. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.

    Article  PubMed  CAS  Google Scholar 

  8. Ishii HH, Gobe GC, Ebihara Y. P53 is an indicator of tumor progression in early but not advanced gastric carcinomas. Hepatogastroenterology. 2007;54(79):2159–63.

    PubMed  Google Scholar 

  9. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev. 2004;30(5):451–9.

    Article  PubMed  CAS  Google Scholar 

  10. Kim JH, Kim MK, Lee HE, et al. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod Pathol. 2007;20:835–42.

    Article  PubMed  CAS  Google Scholar 

  11. Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol. 2008;15(1):69–79.

    Article  PubMed  Google Scholar 

  12. Wang Q, Wen YG, Li DP, et al. Refined mapping of loss of heterozygosity in Chinese sporadic gastric carcinoma. Afr J Biotechnol. 2010;9(35):5754–61.

    CAS  Google Scholar 

  13. Wen YG, Wang Q, Zhou CZ, Qiu GQ, Peng ZH, Tang HM. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3 K/AKT pathway. Oncol Rep. 2010;24:89–95.

    PubMed  CAS  Google Scholar 

  14. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential Ras effector/tumor suppressor of the RASSF family. Cancer Res. 2004;64:8688–93.

    Article  PubMed  CAS  Google Scholar 

  15. Weyden LVD, Adams DJ. The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta. 2007;1776:58–85.

    PubMed  Google Scholar 

  16. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization, Biochim Biophys Acta. 2009;1796:114–28.

    PubMed  CAS  Google Scholar 

  17. Allen NPC, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007;26:6203–11.

    Article  PubMed  CAS  Google Scholar 

  18. Ikeda M, Hirabayashi S, Fujiwara N, et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res. 2007;313:1484–95.

    Article  PubMed  CAS  Google Scholar 

  19. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.

    Article  PubMed  CAS  Google Scholar 

  20. Tsamandas AC, Kardamakis D, Tsiamalos P, et al. The potential role of Bcl-2 expression, apoptosis and cell proliferation (Ki-67 expression) in cases of gastric carcinoma and correlation with classic prognostic factors and patient outcome. Anticancer Res. 2009;29(2):703–9.

    PubMed  Google Scholar 

  21. Sobin LH, Wittekind C. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss; 2002.

    Google Scholar 

  22. Ajani J, D’Amico TA, Hayman JA, Meropol NJ, Minsky B, National Comprehensive Cancer Network. Gastric cancer: Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003;1(1):28–39.

    PubMed  Google Scholar 

  23. Bachmann IM, Puntervoll HE, Otte AP, Akslen LA. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol. 2008;21:583–90.

    Article  PubMed  CAS  Google Scholar 

  24. Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, Sasaki K. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: Its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170:183–9.

    Article  PubMed  CAS  Google Scholar 

  25. Yan DW, Li DW, Yang YX, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II–III disease after curative surgery. Br J Cancer. 2010;103(7):961–9.

    Article  PubMed  CAS  Google Scholar 

  26. Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 2005;65:3497–508.

    Article  PubMed  CAS  Google Scholar 

  27. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J, Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MI B 1 and MI B 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992;168:357–63.

    Article  PubMed  CAS  Google Scholar 

  28. Niimi C, Goto H, Ohmiya N, Niwa Y, Hayakawa T, Nagasaka T, Nakashima N. Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma. Am J Clin Pathol. 2002;118:683–92.

    Article  PubMed  Google Scholar 

  29. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer. 2005;8:86–94.

    Article  PubMed  CAS  Google Scholar 

  30. Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM. Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther. 2006;6:931–9.

    Article  PubMed  Google Scholar 

  31. Jüttner S, Wissmann C, Jöns T, et al. Vascular endothelial growth factor-D and its receptor VEGF-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24:228–40.

    Article  PubMed  Google Scholar 

  32. Huang KH, Chen JH, Wu CW, Lo SS, Hsieh MC, Li AF, Lui WY. Factors affecting recurrence in node-negative advanced gastric cancer. J Gastroenterol Hepatol. 2009;24:1522–6.

    Article  PubMed  Google Scholar 

  33. Baksh S, Tommasi S, Fenton S, et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell. 2005;18:637–50.

    Article  PubMed  CAS  Google Scholar 

  34. Vos MD, Dallol A, Eckfeld K, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem. 2006;281:4557–63.

    Article  PubMed  CAS  Google Scholar 

  35. Hull J, Rowlands K, Lockhart E, Sharland M, Moore C, Hanchard N, Kwiatkowski DP. Haplotype mapping of the bronchiolitis susceptibility locus near IL8. Hum Genet. 2004;114:272–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

This project was supported by the Medical Guidance Research Project of the Science and Technology Commission of Shanghai Municipality (10411967300) and the Doctor Innovation Fund of Shanghai Jiao Tong University School of Medicine (BXJ201045).

Conflict of interest

The authors disclosed no commercial or financial interest in the subject of study.

Author information

Authors and Affiliations

  1. Department of General Surgery, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

    Yugang Wen MD, PhD, Quan Wang MD, PhD, Chongzhi Zhou MD, PhD, Dongwang Yan MD, PhD, Guoqiang Qiu MD & Zhihai Peng MD, PhD

  2. Department of General Surgery, Ningxia Medical University Affiliated Hospital, Yinchuan, Ningxia, People’s Republic of China

    Chun Yang MD, PhD

  3. Department of Pathology, Shanghai First People’s Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China

    Huamei Tang MD

Authors
  1. Yugang Wen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quan Wang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chongzhi Zhou MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dongwang Yan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guoqiang Qiu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chun Yang MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Huamei Tang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhihai Peng MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhihai Peng MD, PhD.

Additional information

Yugang Wen and Quan Wang have contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wen, Y., Wang, Q., Zhou, C. et al. Decreased Expression of RASSF6 Is a Novel Independent Prognostic Marker of a Worse Outcome in Gastric Cancer Patients after Curative Surgery. Ann Surg Oncol 18, 3858–3867 (2011). https://doi.org/10.1245/s10434-011-1668-5

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-011-1668-5

Keywords

Search

Navigation